China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre. COVID global emergency over but risks remain, says China health official (Reuters)…
Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019. The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…
USA Ivan Cheung, head of Japanese firm Eisai’s US operations, highlights the significance of a potential 2021 US FDA approval for Alzheimer’s Disease drug aducanumab, developed in collaboration with Biogen. Cheung also compares the differing challenges of the oncology and neuroscience markets and outlines the unique Eisai company culture. We…
China Fendy Yanhui Feng, vice president of Eisai Co., Ltd. and president of Eisai China Holdings Ltd. and Eisai China Inc., shares the significant improvements she has made to Eisai’s China Region operations over the past five years across; the affiliate’s exciting launch of LENVIMA® in 2018 and more upcoming launches…
UK Confirming Eisai’s commitment to keeping its EMEA headquarters in the UK, Gary Hendler, chairman and CEO EMEA, and Nick Burgin, COO and president of global value and access stress how the company is looking at Brexit as a glass half full. Eisai views Brexit as an opportunity to bring with…
Pharma Raul Vivar, recently appointed GM of Eisai Mexico, describes the main achievements of the Japanese company in Mexico, the challenges that innovative companies face entering the Mexican market, and the development path he will follow in order to foster growth. You took over the helm of the Mexican affiliate of…
Pharma Eisai’s Czech Republic’s Operations Manager discusses the role Eisai plays in the country, the transparency of the pharma industry in the region, and his aspirations for the future. What does the Czech market have to offer Eisai compared to its neighboring countries? The Czech Republic is one of the most…
Eisai Eisai has a history of more than 40 years in Indonesia. In fact, the country was one of the first places for the Group to expand into outside of Japan. Indonesia has already increasingly entered the international spotlight, but how does this apply to Eisai? It seems the Group has…
Eisai Europe As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary Hendler (GH): Eisai are currently present in 17 European markets as Eisai and several others via distributors. However it is…
Eisai France Aricept has been a very effective blockbuster for the group as a whole and the loss of exclusivity affects not only France but entire company. How is Eisai in France going to bridge the gap between this blockbuster and the other developments that are coming down the pipeline? In regard…
See our Cookie Privacy Policy Here